ASPIRE-2-PREVENT: A survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK

Heart

Volumn 98, Issue 11, 2012, Pages 865-871

  Kotseva, Kornelia ^a   Jennings, Catriona S ^a   Turner, Elizabeth L ^b   Mead, Alison ^a   Connolly, Susan ^c   Jones, Jennifer ^a   Bowker, Timothy J ^d   Wood, David A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HEALTH SURVEY; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; SMOKING; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; BODY MASS INDEX; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; FEMALE; GREAT BRITAIN; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MOTOR ACTIVITY; OBESITY; PREVALENCE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 84862093112     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-301603     Document Type: Article

References (30)

1. Wood DA, Durrington P, Poulter N, et al; On behalf of the British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80:S1-29.
2. JBS2. Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl V):1-52.
3. Bowker TJ, Clayton T, Ingham J, et al. A British Cardiac Society survey of the potential for secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996;75:334-42.
4. Kotseva K, Wood D, De Backer G, et al; On behalf of EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from twenty two European countries. EUROASPIRE Study Group. Eur J Cardiovasc Prev Rehabil 2009;16:121-37.
5. Kotseva K, Wood D, De Backer G, et al; On behalf of EUROASPIRE Study Group. Cardiovascular prevention guidelinesdthe clinical reality: a comparison of EUROASPIRE I, II and III surveys in 8 European countries. Lancet 2009;372: 929-40.
6. Kotseva K, Wood D, De Backer G, et al; On behalf of EUROASPIRE Study Group. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high risk subjects in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010;17:530-40.
7. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-43.
8. Wilson K, Gibson N, Willan A, et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000;160:939-44. (Pubitemid 30191921)
9. Chow C, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121:750-8.
10. Hooper L, Griffiths E, Abrahams B, et al. Dietetic guidelines: diet in secondary prevention of cardiovascular disease. J Hum Nutr Dietet 2004;17:337-49. (Pubitemid 39136776)
11. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Cardiovasc Prev Rehabil 2008;15:336-40.
12. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-45.
13. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3.
14. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
15. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-9.
16. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
17. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
18. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
19. Löwel H, König W, Engel S, et al. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 2000;43:218-26. (Pubitemid 30126827)
20. Mukamal KJ, Nesto RW, Cohen MC, et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability or risk with prior myocardial infarction. Diabetes Care 2001;24:1422-7. (Pubitemid 33716431)
21. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
22. Department of Health. Quality and Outcomes Framework. http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/documents/ digitalasset/dh-4088693.pdf
23. Heran BS, Chen JMH, Ebrahim S, et al. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2011;(7):CD001800.
24. Clark A M, Hartling L, Vandermeer B, et al. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005;143:659-72.
25. McAlsiter FA, Lawson FME, Teo KK, et al. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ 2001;323:957-62. (Pubitemid 33016042)
26. Department of Health. Putting Prevention First. NHS Health Check: Vascular Risk Assessment and Management. Best Practice Guidance. http://www.dh.gov.uk/publications
27. Ebrahim S, Beswick A, Burke M, et al. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2006;(4):CD001561.
28. Wood DA, Kotseva K, Connolly S, et al; On behalf of the EUROACTION Study Group. Nurse-coordinated multidisciplinary, family based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired cluster randomised controlled trial. Lancet 2008;371:1999-2012. (Pubitemid 351799857)
29. Godin G, Shephard RJ. Godin leisure-time exercise questionnaire. Med Sci Sports Exerc 1997;29:S36-8.
30. Connolly S, Holden A, Turner E, et al. MyAction: an innovative approach to the prevention of cardiovascular disease in the community. Br J Cardiol 2011;18:171-6.